Quidel Corp (QDEL) Gets a Buy Rating from Piper Jaffray


Piper Jaffray analyst William Quirk reiterated a Buy rating on Quidel Corp (NASDAQ: QDEL) yesterday and set a price target of $74. The company’s shares closed yesterday at $71.69, close to its 52-week high of $73.36.

According to TipRanks.com, Quirk is a 5-star analyst with an average return of 18.6% and a 69.7% success rate. Quirk covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Pacific Biosciences, and Idexx Laboratories.

Currently, the analyst consensus on Quidel Corp is a Strong Buy with an average price target of $75.67, a 5.6% upside from current levels. In a report issued on August 3, Barclays also maintained a Buy rating on the stock with a $78 price target.

.

See today’s analyst top recommended stocks >>

Quidel Corp’s market cap is currently $2.68B and has a P/E ratio of 358.45. The company has a Price to Book ratio of 8.11.

Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Thomas D. Brown, a Director at QDEL sold 30,451 shares for a total of $1,867,864.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes immunoassays, molecular diagnostics, virology, and specialty products. Immunoassay tests are for physician offices, hospital laboratories, emergency departments, pharmacies, and other urgent care or alternative site settings.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts